Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Supriya Lifescience Limited ( (IN:SUPRIYA) ) has provided an update.
Supriya Lifescience Limited notified the stock exchanges that it has published a notice of postal ballot in major newspapers as part of its regulatory obligations. The advertisement appeared on 11 March 2026 in the Financial Express and Loksatta, underscoring the company’s compliance with Securities and Exchange Board of India listing and disclosure requirements and keeping shareholders informed of ongoing corporate actions.
The move reinforces transparency in the company’s corporate governance and ensures that shareholders are formally updated through widely circulated English and regional language publications. By documenting the dispatch and publication of the postal ballot notice, Supriya Lifescience aims to maintain robust engagement with investors and align with best practices expected of listed entities on BSE and NSE.
More about Supriya Lifescience Limited
Supriya Lifescience Limited is an Indian pharmaceutical company focused on manufacturing and exporting active pharmaceutical ingredients and related products. Recognised as a government-approved export house, it operates from a corporate office in Mumbai and a manufacturing facility in Maharashtra, serving both domestic and international healthcare markets.
Average Trading Volume: 7,272
Technical Sentiment Signal: Sell
Current Market Cap: 48.67B INR
For a thorough assessment of SUPRIYA stock, go to TipRanks’ Stock Analysis page.